ITRM - Iterum outlines ORLYNVAH's market potential with exclusivity through 2034
2025-02-07 10:20:46 ET
More on Iterum Therapeutics
- Iterum Therapeutics plc (ITRM) Q4 2024 Earnings Call Transcript
- Iterum Therapeutics plc (ITRM) Q3 2024 Earnings Call Transcript
- Iterum Therapeutics Non-GAAP EPS of -$0.12 beats by $0.12
- Seeking Alpha’s Quant Rating on Iterum Therapeutics
- Historical earnings data for Iterum Therapeutics